Properties of galactosemic cells in culture

Oxidation of galactose by galactose-1-phosphate uridyltransferase-deficient lymphoblasts

The ability of EB virus-transformed lymphoblasts with undetectable galactose-1-phosphate uridyltransferase (GALT) from 15 galactosaemic patients to oxidize [1-(14)C]galactose to 14CO2 was compared to that of cells from 7 normal subjects. The oxidation of galactose but not of glucose was markedly diminished by cells from Q188R homozygous galactosaemic patients but was not absent. After 2.5 h these cells liberated 14CO2 at nearly 3% and at 5 h up to 9% of normal. Cells from patients homozygous for the S135L mutation produced much larger amounts of 14CO2 (15-17% of normal) and were distinguishable from the Q188R homozygous cells. A cell line with a homozygous deletion of the GALT gene oxidized galactose at 7% of the normal rate, suggesting that pathways(s) other than GALT exist in these cells as well as Q188R homozygous cells for oxidation of galactose to CO2. Concentration dependence studies are consistent with the presence of a pathway that is unsaturable or has a very high Km The ability of 10(7) lymphoblasts with the S135L genotype to oxidize more than 7% of the sugar to 14CO2 in 5 h suggests the presence of residual GALT despite the inability to detect the activity by enzymatic analysis.

Studies on cell lines developed from the tissues of patients with galactosemia

Cell lines were developed from biopsies on galactosemic and non-galactosemic patients. It was shown that one can discriminate between lines from the two types of donors by their relative growth in glucose and galactose and by their ability to oxidize galactose-1-C¹⁴. The latter method was successful in distinguishing a heterozygous cell line from the normal ones. Sensitivity of galactosemic cells to galactose was suggested by some of the experiments. The kinetics of growth were in some ways reminiscent of a similar phenomenon in the transferase mutants of E. coli, though in the human cells the effect was much less marked.

Galactose metabolism in transferase-deficient galactosaemic and normal long-term lymphoid cell lines

The activity (mean +/- SD) of galactose-1-phosphate uridyl transferase in two long-term lymphoid cell lines from Caucasian patients with transferase deficiency galactosaemia, a heterozygote, and eight normal subjects was 0, 78 and 168 +/- 55 nmol UDPG consumed (mg protein)-1h-1, respectively. Also, no activity was found in erythrocytes and cultured fibroblasts from the patients. A small number of cells of the galactosaemic lines cultured in medium, in which galactose was substituted for glucose, survived for 37 days. Normal and galactosaemic lines incubated with D-galactose-[1-14C] liberated 218.2 +/- 65.6 and 18.1 pmol 14CO2 (mg cellular protein)-1 (6h)-1, respectively. The evolution of 14CO2 from D-glucose-[1-14C] was similar in normal and galactosaemic lines. In the presence of [3H]galactose the radioactivity incorporated into TCA-precipitated material of the galactosaemic lines was 6.8% of the normal lines. Approximately 26% and 1.3% of the total radioactivity was incorporated into molecular species with a molecular weight greater than 400,000 daltons in normal and galactosaemic cells, respectively. Similar molecules were identified in the cell-free medium of both normal and deficient cells except for an 18,000 daltons molecule identified only in the medium of the normal cells. These findings indicate that a small amount of galactose is metabolized in galactosaemic lines with no transferase activity.

The mucopolysaccharidoses (a review)

The mucopolysaccharidoses are a group of genetic diseases characterized by storage of incompletely degraded glycosaminoglycans. Such storage causes marked distortion of many tissues with consequent severe somatic changes and mental retardation. Storage of glycosaminoglycans results from markedly diminished activity of specific hydrolases requisite for the normal degradation of glycosaminoglycans. The specific enzymic defects have been identified in nine different diseases. In some cases evidence has been obtained indicating the existence of additional allelic diseases based on the same enzyme. The knowledge obtained from these studies has made prenatal diagnosis possible and has led to the possibility that therapy may be undertaken utilizing enzyme replacement.

Galactose and glucose metabolism in galactokinase deficient, galactose-1-P-uridyl transferase deficient and normal human fibroblasts

Despite the genetic interruption of the Leloir pathway both galactosemic patients and galactosemic fibroblasts can convert galactose to CO2 and TCA precipitable products, although at less than the normal rate. These observations stimulated investigations into the identity of the alternative metabolic routes which allows for galactose metabolism in the absence of in vitro galactose-1-P-uridyl transferase. Four lines of galactosemic cells, each without detectable gal-transferase, produced 14CO2 from [1-14C]-galactose (0.094 mumoles in 20 cc of medium) at approximately 39% +/- 16% the rate of transferase positive cells over a 48-hour period. However, galactokinase deficient fibroblasts produced 14CO2 and TCA precipitable products from [1-14C]-galactose or [U-14C]-galactose at only 3% to 9% the rate of normal fibroblasts. Therefore it seems likely that gal-transferase deficient fibroblasts must first synthesize galactose-1-P for further metabolism of galactose.

Galactose utilization in galactosemia

Cultures of human galactosemic fibroblasts without detectable transferase activity were able to convert [1-(14)C]galactose to (14)CO(2) to the same extent as normal cells, but did so at a significantly slower rate. The utilization of galactose in both normal and galactosemic cells was strongly inhibited by glucose at physiologic concentrations.